Table 2.
One-Year Rates of Cardiovascular Diseases Contraindicating Use of Triptans in Migraine Patients (2017 Data).
| Optum CDM N = 56 662 | MarketScan N = 176 724 | |
|---|---|---|
| ≥1 contraindication listed in triptan label | 7653 (13.5) | 21 495 (12.2) |
| Cerebrovascular/cardiovascular disease | 3830 (6.8) | 10 495 (5.9) |
| Ischemic cerebrovascular disease | 3085 (5.4) | 8482 (4.8) |
| Other cerebrovascular disease | 1369 (2.4) | 3683 (2.1) |
| Uncontrolled hypertension | 2324 (4.1) | 6154 (3.5) |
| Ischemic heart disease | 2136 (3.8) | 5751 (3.3) |
| Peripheral artery disease | 1409 (2.5) | 3885 (2.2) |
| Gastrointestinal ischemia | 51 (0.1) | 128 (0.1) |
| ≥1 contraindication considered as “other significant cardiovascular disease” in triptan label | 4833 (8.5) | 14 180 (8.0%) |
| Structural heart disease | 3113 (5.5) | 8737 (4.9) |
| Arrhythmias | 2582 (4.6) | 7369 (4.2) |
| Cardiac surgery | 484 (0.9) | 1031 (0.6) |
| Other cardiac condition | 4244 (7.5) | 11 037 (6.2) |
| ≥1 contraindication listed in triptan label or considered as “other significant cardiovascular disease” in triptan label | 12 486 (22.0) | 35 675 (20.2) |
Abbreviations: CDM: Clinformatics Data Mart.
All data are n (%). Diagnosis codes included within each disease category are listed in Supplemenatal Tables S1 and S2 in the supplementary material.